Label-free in vivo molecular imaging of underglycosylated mucin-1 expression in tumour cells

Nature Communications

Volumn 6, Issue , 2015, Pages

  Song, Xiaolei ^a   Airan, Raag D ^a   Arifin, Dian R ^a   Bar Shir, Amnon ^a   Kadayakkara, Deepak K ^a   Liu, Guanshu ^a,b   Gilad, Assaf A ^a   Van Zijl, Peter C M ^a,b   McMahon, Michael T ^a,b   Bulte, Jeff W M ^a,b,c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

^c Johns Hopkins University   (United States)

^d Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED PROTEIN; MUCIN 1; MUC1 PROTEIN, HUMAN;

BRAIN; CANCER; CHEMICAL PROCESS; GENE EXPRESSION; IMAGING METHOD; MOLECULAR ANALYSIS; POLYMER; RODENT; TUMOR;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CELL ENCAPSULATION; CONTROLLED STUDY; DEGLYCOSYLATION; EPITHELIUM CELL; HT 29 CELL LINE; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR OVERHAUSER EFFECT; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA; GLYCOSYLATION; HT-29 CELL LINE; METABOLISM; PATHOLOGY; PROCEDURES; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; GLYCOSYLATION; HT29 CELLS; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, SCID; MOLECULAR IMAGING; MUCIN-1; NEOPLASM TRANSPLANTATION;

EID: 84925605683     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7719     Document Type: Article

References (45)

1. Hattrup, C. L. & Gendler, S. J. Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 70, 431-457 (2008).
2. Kufe, D. W. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 9, 874-885 (2009).
3. Hollingsworth, M. A. & Swanson, B. J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 4, 45-60 (2004).
4. Ren, J. et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 5, 163-175 (2004).
5. Siragusa, M. et al. MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res. 67, 5522-5530 (2007).
6. Taylor-Papadimitriou, J., Burchell, J., Miles, D. W. & Dalziel, M. MUC1 and cancer. Biochim. Biophys. Acta Mol. Dis. 1455, 301-313 (1999).
7. Bansil, R., Stanley, E. & LaMont, J. T. Mucin biophysics. Annu. Rev. Physiol. 57, 635-657 (1995).
8. Brayman, M., Thathiah, A. & Carson, D. D. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod. Biol. Endocrinol. 2, 4 (2004).
9. Lloyd, K. O., Burchell, J., Kudryashov, V., Yin, B. W. T. & TaylorPapadimitriou, J. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines-Demonstration of simpler and fewer glycan chains in tumor cells. J. Biol. Chem. 271, 33325-33334 (1996).
10. Burchell, J. & Taylor-Papadimitriou, J. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol. 2, 155-162 (1993).
11. BarrattBoyes, S. M. Making the most of mucin: A novel target for tumor immunotherapy. Cancer Immunol. Immunother. 43, 142-151 (1996).
12. Kontani, K. et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int. J. Mol. Med. 12, 493-502 (2003).
13. Peterson, J. A., Blank, E. W. & Ceriani, R. L. Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (Breast MUC-1 mucin) in breast carcinomas. Cancer Res. 57, 1103-1108 (1997).
14. Li, Y. & Cozzi, P. J. MUC1 is a promising therapeutic target for prostate cancer therapy. Curr. Cancer Drug Targets 7, 259-271 (2007).
15. Pietersz, G. A. et al. Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy. Cancer Immunol. Immunother. 44, 323-328 (1997).
16. Hird, V. et al. Adjuvant therapy of ovarian-cancer with radioactive monoclonal-antibody. Br. J. Cancer 68, 403-406 (1993).
17. Hussain, R., Courtenay-Luck, N. S. & Siligardi, G. Structure-function correlation and biostability of antibody CDR-derived peptides as tumour imaging agents. Biomed. Pept. Proteins Nucleic Acids 2, 67-70 (1996).
18. Gendler, S. J. et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 265, 15286-15293 (1990).
19. Imai, K. et al. MUC1 as a human tumor marker. N. Dev. Glycomed. 1223, 125-133 (2001).
20. Sivolapenko, G. B. et al. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody. Lancet 346, 1662-1666 (1995).
21. Moore, A., Medarova, Z., Potthast, A. & Dai, G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res. 64, 1821-1827 (2004).
22. Ghosh, S. K., Pantazopoulos, P., Medarova, Z. & Moore, A. Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues. Clin. Breast Cancer 13, 109-118 (2013).
23. Ward, K. M., Aletras, A. H. & Balaban, R. S. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J. Magn. Reson. 143, 79-87 (2000).
24. van Zijl, P. C. & Yadav, N. N. Chemical exchange saturation transfer (CEST): what is in a name and what isn't? Magn. Reson. Med. 65, 927-948 (2011).
25. Liu, G., Song, X., Chan, K. W. & McMahon, M. T. Nuts and bolts of chemical exchange saturation transfer MRI. NMR Biomed. 26, 810-828 (2013).
26. Chan, K. W. et al. Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. Magn. Reson. Med. 68, 1764-1773 (2012).
27. Walker-Samuel, S. et al. In vivo imaging of glucose uptake and metabolism in tumors. Nat. Med. 19, 1067-1072 (2013).
28. Rivlin, M., Horev, J., Tsarfaty, I. & Navon, G. Molecular imaging of tumors and metastases using chemical exchange saturation transfer (CEST) MRI. Sci. Rep. 3, 3045 (2013).
29. Cai, K. et al. Magnetic resonance imaging of glutamate. Nat. Med. 18, 302-306 (2012).
30. van Zijl, P. C., Jones, C. K., Ren, J., Malloy, C. R. & Sherry, A. D. MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST). Proc. Natl Acad. Sci. USA 104, 4359-4364 (2007).
31. Ling, W., Regatte, R. R., Navon, G. & Jerschow, A. Assessment of glycosaminoglycan concentration in vivo by chemical exchange-dependent saturation transfer (gagCEST). Proc. Natl Acad. Sci. USA 105, 2266-2270 (2008).
32. Saar, G. et al. Assessment of glycosaminoglycan concentration changes in the intervertebral disc via chemical exchange saturation transfer. NMR Biomed. 25, 255-261 (2012).
33. Shinar, H. et al. Sialo-CEST: chemical exchange saturation transfer NMR of oligo- and poly-sialic acids and the assignment of their hydroxyl groups using selective- and HSQC-TOCSY. Carbohydr. Res. 389, 165-173 (2014).
34. Jin, T., Autio, J., Obata, T. & Kim, S.-G. Spin-locking versus chemical exchange saturation transfer MRI for investigating chemical exchange process between water and labile metabolite protons. Magn. Reson. Med. 65, 1448-1460 (2011).
35. van Sluis, R. et al. In vivo imaging of extracellular pH using 1H MRSI. Magn. Reson. Med. 41, 743-750 (1999).
36. Raju, T. S. & Davidson, E. A. New approach towards deglycosylation of sialoglycoproteins and mucins. Biochem. Mol. Biol. Int. 34, 943-954 (1994).
37. Edge, A. S. Deglycosylation of glycoproteins with trifluoromethanesulphonic acid: elucidation of molecular structure and function. Biochem. J. 376, 339-350 (2003).
38. Osset, M., Pinol, M., Fallon, M. J., de Llorens, R. & Cuchillo, C. M. Interference of the carbohydrate moiety in coomassie brilliant blue R-250 protein staining. Electrophoresis 10, 271-273 (1989).
39. Jones, C. K. et al. Nuclear overhauser enhancement (NOE) imaging in the human brain at 7T. NeuroImage 77, 114-124 (2013).
40. Paech, D. et al. Nuclear overhauser enhancement mediated chemical exchange saturation transfer imaging at 7 Tesla in glioblastoma patients. PLoS ONE 9, e104181 (2014).
41. Song, X. et al. CEST phase mapping using a length and offset varied saturation (LOVARS) scheme. Magn. Reson. Med. 68, 1074-1086 (2012).
42. Song, X. et al. Multi-echo Length and Offset VARied Saturation (MeLOVARS) method for improved CEST imaging. Magn. Reson. Med. 73, 488-496 (2014).
43. Dula, A. N. et al. Amide proton transfer imaging of the breast at 3T: establishing reproducibility and possible feasibility assessing chemotherapy response. Magn. Reson. Med. 70, 216-224 (2013).
44. Hanson, J. M. et al. MUC1 expression in primary breast cancer: the effect of tamoxifen treatment. Breast Cancer Res. Treat. 67, 215-222 (2001).
45. Ghosh, S. K. et al. Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model. Int. J. Cancer 132, 1860-1867 (2013).